Truvian Sciences Inc.

Founded in 2015, Truvian Sciences Inc. specializes in automated blood diagnostics, offering innovative solutions for rapid and accurate health testing to enhance patient care. Truvian Sciences Inc. is a private company based in San Diego, California, focusing on developing automated blood testing solutions.

The founders, Dena Marrinucci, Drew Spaventa, and Pieter van Rooyen, have pooled their expertise to advance the field of diagnostics. The company has secured a total of USD 67. 58 mn in funding through multiple rounds, with its latest funding being a Series D round concluded on May 2, 2024. Notably, Truvian has undertaken three different deals to date, with prominent investors including Wittington Ventures and Great Point Ventures, reflecting ongoing confidence in its business model.

Currently, the company is valued at USD 287. 96 mn. Truvian is pioneering innovation in blood diagnostics with its automated benchtop blood testing analyzer, which delivers lab-accurate results from just a few drops of blood. This device simplifies routine health testing, providing key tests such as complete blood count, comprehensive metabolic panel, lipid panel, hemoglobin A1c, and TSH in a single run.

Targeting healthcare providers in the United States, Truvian's technology aims to enhance the efficiency of patient care by enabling immediate results during consultations. Truvian generates revenue through the sale of its benchtop blood testing analyzer and associated disposable test kits required for testing. Its business model is primarily B2B, focusing on healthcare providers who implement these solutions in-house to optimize testing workflows. While specific pricing details are undisclosed, the revenue structure is expected to include direct sales and potential subscription agreements for test kits, aiming to streamline routine blood testing access for healthcare professionals and their patients.

In May 2024, Truvian Sciences Inc. raised USD 67. 58 mn in Series D funding, co-led by returning investors Wittington Ventures and Great Point Ventures, with participation from additional investors. This funding will support the advancement of clinical trials aimed at securing FDA clearance for its blood testing platform.

The company is focused on launching new products that will further enhance its diagnostic capabilities and plans to expand into additional markets, aiming for broader geographical reach in the upcoming years.